The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 ...

We recently compiled a list of the Jim Cramer Talked About These 11 Stocks Recently. In this article, we are going to take a ...

The drug company had been searching for a new chief scientific officer since July with Mikael Dolsten leaving after 15 years ...

Pfizer's stock appears undervalued with a high dividend yield of 6.8%, making it a potential long-term investment despite low growth expectations. The company reported strong Q3 results with 31.2% YoY ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Meta Platforms Inc, Pfizer Inc and American Airlines are among the companies the Labor Department’s contractor watchdog has ...

Pfizer's drug approvals and advertising revenue could be affected by RFK Jr.'s potential appointment. See why PFE stock is a ...

Dividend stocks have long been favored by investors for the income they generate, and they become even more appealing when ...

Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer ...

BridgeBio Pharma Inc. gained US approval for a drug to treat a progressive and deadly form of heart disease, paving the way ...

Drug major Pfizer Inc. (PFE) announced Wednesday the appointment of Chris Boshoff as Chief Scientific Officer and President, Research ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with ...